Name | N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1H-pyridine-3-carboxamide |
---|---|
Synonyms |
3-Pyridinecarboxamide, N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-5-(4-fluorophenyl)-1,4-dihydro-4-oxo-
N-{4-[(2-Amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl}-5-(4-fluorophenyl)-4-oxo-1,4-dihydro-3-pyridinecarboxamide BMS-794833 |
Description | BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC50s of 15 and 1.7 nM, respectively. |
---|---|
Related Catalog | |
Target |
VEGFR2:15 nM (IC50) Met:1.7 nM (IC50) |
In Vitro | BMS794833 inhibits Met receptor activated gastric carcinoma cell line, GTL-16, with an IC50 of 39 nM[1]. |
In Vivo | BMS-794833 is active by greater than 50% tumor growth inhibition for at least one tumor doubling time in the GTL-16 gastric carcinoma model. No toxicity is observed at any of the dose levels when administered once daily for a duration of 14 days[1]. |
Cell Assay | GTL-16 cells are inoculated in to 96 well microtiter plates in 0.5% fetal calf serum and incubated at 37°C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of a compound. Cells are treated with BMS-794833 for an additional 72 h. Growth inhibition is calculated[1]. |
References |
[1]. WO2009094417 |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 637.2±55.0 °C at 760 mmHg |
Molecular Formula | C23H15ClF2N4O3 |
Molecular Weight | 468.840 |
Flash Point | 339.2±31.5 °C |
Exact Mass | 468.080078 |
PSA | 114.32000 |
LogP | 4.26 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.681 |
Storage condition | -20℃ |